Skip to main content
SpringerLink
Log in

Micronutrients in Cancer Chemoprevention

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

The selection of micronutrients, defined as essential and nonessential dietary components consumed in minute quantities, for testing in clinical chemoprevention trials is based on the totality of evidence arising from epidemiologic, in vitro, animal, and clinical studies. Those micronutrients that surface with chemopreventive potential, in terms of high efficacy and low toxicity, in early-phase clinical studies are then candidates for large-scale, randomized clinical chemoprevention trials with cancer endpoints. Micronutrients currently being examined in National Cancer Institute (NCI)-sponsored phase I, II, or III chemoprevention trials for prostate, breast, and colon cancers include isoflavones, lycopene, selenized yeast, selenomethionine, selenium, vitamin E, perillyl alcohol, folic acid, vitamin D, calcium, and curcumin. The response to micronutrients may vary not only in magnitude but also in direction. This variation and response likely depend on individual genetic polymorphisms and/or interactions among dietary components that influence absorption, metabolism, or site of action. Research priorities include investigation of possible molecular targets for micronutrients and whether genetic and epigenetic events dictate direction and magnitude of the response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90: 1219–1224, 1998

    Google Scholar 

  2. Helzlsouer KJ, Huang H-Y, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW: Association between α-tocopherol, γ-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92: 2018–2023, 2000

    Google Scholar 

  3. Nomura AMY, Lee J, Stemmermann GN, Combs GF, Jr.: Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9: 883–887, 2000

    Google Scholar 

  4. Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, Taylor PR: The association between baseline vitamin E, selenium, and prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomark Prev 7: 335–340, 1998

    Google Scholar 

  5. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS: Carotene and Retinol Efficacy Trial (CARET) Co-Investigators: Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1069–1076, 2001

    Google Scholar 

  6. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., Park HK, Sanders BB, Jr., Smith CL, Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276: 1957–1963, 1996

    Google Scholar 

  7. Clark LC, Dalkin B, Krongrad A, Combs GF, Jr., Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J: Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81: 730–734, 1998

    Google Scholar 

  8. Cohen LA (ed): Selenium and Cancer, Larry C. Clark Memorial Issue. Nutr Cancer 40: 1–78, 2001

  9. Menter DG, Sabichi AL, Lippman SM: Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9: 1171–1182, 2000

    Google Scholar 

  10. Zhong W, Oberley TD: Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61: 7071–7078, 2001

    Google Scholar 

  11. Weber P, Bendich A, Machlin LJ: Vitamin E and human health: Rationale for determining recommended intake levels. Nutrition 13: 450–460, 1997

    Google Scholar 

  12. Chan JM, Stampfer MJ, Giovannucci EL: What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 8: 263–273, 1998

    Google Scholar 

  13. Eichholzer M, Stahelin HB, Ludin E, Bernasconi F: Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: Seventeen-year follow-up of the prospective Basel study. Prostate 38: 189–198, 1999

    Google Scholar 

  14. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL: Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomark Prev 8: 893–899, 1999

    Google Scholar 

  15. Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE: Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8: 887–892, 1999

    Google Scholar 

  16. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK: Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440–446, 1998

    Google Scholar 

  17. Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group, Heinonen OP, Huttunen JK, Albanes D: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029–1035, 1994

    Google Scholar 

  18. Kline K, Yu W, Sanders BG: Vitamin E: Mechanisms of action as tumor cell growth inhibitors. J Nutr 131: 161S–163S, 2001

    Google Scholar 

  19. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C: SELECT: The next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166: 1311–1315, 2001

    Google Scholar 

  20. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM: Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12: 627–633, 2001

    Google Scholar 

  21. Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis. Cancer Causes Control 9: 567–582, 1998

    Google Scholar 

  22. Platz EA, Giovannucci E: Vitamin D and calcium in colorectal and prostate cancers. In: Heber D, Blackburn GL, Go VLW(eds) Nutritional Oncology. Academic Press, San Diego, 1999, pp 223–252

    Google Scholar 

  23. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL: Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 74: 549–554, 2001

    Google Scholar 

  24. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847–852, 2000

    Google Scholar 

  25. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56: 4108–4110, 1996

    Google Scholar 

  26. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170, 1997

    Google Scholar 

  27. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 58: 1620–1623, 1998

    Google Scholar 

  28. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 60: 305–308, 2000

    Google Scholar 

  29. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev 7: 385–390, 1998

    Google Scholar 

  30. Barreto AM, Schwartz GG, Woodruff R, Cramer SD: 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9: 265–270, 2000

    Google Scholar 

  31. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ: Growth inhibitory effects of 1α, 25-dihydroxyvitamin D3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61: 7122–7129, 2001

    Google Scholar 

  32. Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG, Williams AW, Moore BJ, Erdman JW, Jr.: cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomark Prev 5: 823–833, 1996

    Google Scholar 

  33. Giovannucci E: Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 91: 317–331, 1999

    Google Scholar 

  34. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ: Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 59: 1225–1230, 1999

    Google Scholar 

  35. Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon-Cardo C, Scher HI, Marshall JR, Zhang ZF: Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 10: 749–756, 2001

    Google Scholar 

  36. Pastori M, Pfander H, Boscoboinik D, Azzi A: Lycopene in association with α-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun 250: 582–585, 1998

    Google Scholar 

  37. Fournier DB, Erdman JW, Jr., Gordon GB: Soy, its components, and cancer prevention: A review of the in vitro, animal, and human data. Cancer Epidemiol Biomark Prev 7: 1055–1065, 1998

    Google Scholar 

  38. Jacobsen BK, Knutsen SF, Fraser GE: Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9: 553–557, 1998

    Google Scholar 

  39. Pillow PC, Duphorne CM, Chang S, Contois JH, Strom SS, Spitz MR, Hursting SD: Development of a database for assessing dietary phytoestrogen intake. Nutr Cancer 33: 3–19, 1999

    Google Scholar 

  40. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, Hursting SD: Phytoestrogen intake and prostate cancer:Acase-control study using a new database. Nutr Cancer 33: 20–25, 1999

    Google Scholar 

  41. Mitchell JH, Duthie SJ, Collins AR: Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr Cancer 38: 223–228, 2000

    Google Scholar 

  42. Zhou J-R, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129: 1628–1635, 1999

    Google Scholar 

  43. Davis JN, Singh B, Bhuiyan M, Sarkar FH: Genistein-induced upregulation of p21WAFI, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32: 123–131, 1998

    Google Scholar 

  44. Mentor-Marcel R, Lamartiniere CA, Eltoum I-E, Greenberg NM, Elgavish A: Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61: 6777–6782, 2001

    Google Scholar 

  45. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98: 10350–10355, 2001

    Google Scholar 

  46. Gupta S, Ahmad N, Mohan RR, Husain MM, Mukhtar H: Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 59: 2115–2120, 1999

    Google Scholar 

  47. Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA: Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 38: 116–122, 2000

    Google Scholar 

  48. Xing N, Chen Y, Mitchell SH, Young CYF: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22: 409–414, 2001

    Google Scholar 

  49. Mitchell SH, Zhu W, Young CYF: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892–5895, 1999

    Google Scholar 

  50. Wu AH, Ziegler RG, Nomura AM, West DW, Kolonel LN, Horn-Ross PL, Hoover RN, Pike MC: Soy intake and risk of breast cancer in Asians and Asian-Americans. Am J Clin Nutr 68: 1437S–1443S, 1998

    Google Scholar 

  51. Messina MJ, Loprinzi CL: Soy for breast cancer survivors: A critical review of the literature. J Nutr 131: 3095S–3108S, 2001

    Google Scholar 

  52. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AMY, West DW, Kolonel LN, Rosenthal JF, Hoover RN, Pike MC: Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomark Prev 5: 901–906, 1996

    Google Scholar 

  53. Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda LC, Shiau AC, Goldstein J, Davis P, Perez-Stable EJ: Phytoestrogen consumption and breast cancer risk in a multiethnic population: The Bay Area Breast Cancer Study. Am J Epidemiol 154: 434–441, 2001

    Google Scholar 

  54. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT, Zheng W: Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 10: 483–488, 2001

    Google Scholar 

  55. Zheng W, Dai Q, Custer LJ, Shu X-O, Wen W-Q, Jin F, Franke AA: Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomark Prev 8: 35–40, 1999

    Google Scholar 

  56. den Tonkelaar I, Keinan-Boker L, van't Veer P, Arts CJM, Adlercreutz H, Thijssen JHH, Peeters PHM: Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 223–228, 2001

    Google Scholar 

  57. Xu X, Duncan AM, Wangen KE, Kurzer MS: Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 9: 781–786, 2000

    Google Scholar 

  58. Lu L-JW, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE: Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 60: 1299–1305, 2000

    Google Scholar 

  59. Kishida T, Beppu M, Nashiki K, Izumi T, Ebihara K: Effect of dietary soy isoflavone aglycones on the urinary 16-alphato-2-hydroxyestrone ratio in C3H/HeJ mice. Nutr Cancer 38: 209–214, 2000

    Google Scholar 

  60. Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, De Fronzo G: Genistein in the control of breast cancer cell growth: Insights into the mechanism of action in vitro. Cancer Lett 130: 143–152, 1998

    Google Scholar 

  61. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG: Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 61: 5045–5050, 2001

    Google Scholar 

  62. Kim Y-I: Folate and carcinogenesis: Evidence, mechanisms, and implications. J Nutr Biochem 10: 66–88, 1999

    Google Scholar 

  63. Choi S-W, Mason JB: Folate and carcinogenesis: An integrated scheme. J Nutr 130: 129–132, 2000

    Google Scholar 

  64. Wu K, Helzlsouer KJ, Comstock GW, Hoffman SC, Nadeau MR, Selhub J: A prospective study on folate, B12, and pyridoxal 5′-phosphate (B6) and breast cancer. Cancer Epidemiol Biomark Prev 8: 209–217, 1999

    Google Scholar 

  65. Shrubsole MJ, Jin F, Dai Q, Shu X-O, Potter JD, Hebert JR, Gao Y-T, Zheng W: Dietary folate intake and breast cancer risk: Results from the Shanghai Breast Cancer Study. Cancer Res 61: 7136–7141, 2001

    Google Scholar 

  66. Freudenheim JL, Marshall JR, Vena JE, Laughlin R, Brasure JR, Swanson MK, Nemoto T, Graham S: Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Inst 88: 340–348, 1996

    Google Scholar 

  67. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE, Willett WC: A prospective study of folate intake and the risk of breast cancer. JAMA 281: 1632–1637, 1999

    Google Scholar 

  68. Rohan TA, Jain MG, Howe GR, Miller AB: Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 92: 266–269, 2000

    Google Scholar 

  69. Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, Vachon CM, Olson JE, Therneau TM, Folsom AR: Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 12: 420–428, 2001

    Google Scholar 

  70. Zhu K, Williams SM: Methyl-deficient diets, methylated ER genes and breast cancer: An hypothesized association. Cancer Causes Control 9: 615–620, 1998

    Google Scholar 

  71. Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD: COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 22: 1661–1665, 2001

    Google Scholar 

  72. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC: Clinical development plans for cancer chemopreventive agents: l-perillyl alcohol. J Cell Biochem 26S(Suppl): 137–148, 1996

    Google Scholar 

  73. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129: 775S–778S, 1999

    Google Scholar 

  74. Bardon S, Picard K, Martel P: Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32: 1–7, 1998

    Google Scholar 

  75. Haag JD, Gould MN: Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34: 477–483, 1994

    Google Scholar 

  76. Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN: Activation of the transforming growth factor β signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59: 1917–1928, 1999

    Google Scholar 

  77. Toniolo P, van Kappel AL, Akhmedkhanov A, Ferrari P, Kato I, Shore RE, Riboli E: Serum carotenoids and breast cancer. Am J Epidemiol 153: 1142–1147, 2001

    Google Scholar 

  78. Hultén K, van Kappel AL, Winkvist A, Kaaks R, Hallmans G, Lenner P, Riboli E: Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in northern Sweden. Cancer Causes Control 12: 529–537, 2001

    Google Scholar 

  79. Kim MK, Ahn SH, Lee-Kim YC: Relationship of serum α-tocopherol, carotenoids and retinol with the risk of breast cancer. Nutr Res 21: 797–809, 2001

    Google Scholar 

  80. Dorgan JF, Sowell A, Swanson CA, Potischman N, Miller R, Schussler N, Stephenson HE, Jr.: Relationships of serum carotenoids, retinol, α-tocopherol, and selenium with breast cancer risk: Results from a prospective study in Columbia, Missouri (United States). Cancer Causes Control 9: 89–97, 1998

    Google Scholar 

  81. Levi F, Pasche C, Lucchini F, La Vecchia C: Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer 91: 260–263, 2001

    Google Scholar 

  82. Ronco A, De Stefani E, Boffetta P, Deneo-Pellegrini H, Mendilaharsu M, Leborgne F: Vegetables, fruits, and related nutrients and risk of breast cancer: A case-control study in Uruguay. Nutr Cancer 35: 111–119, 1999

    Google Scholar 

  83. Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, Manson JE, Hankinson SE, Willett WC: Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 91: 547–556, 1999

    Google Scholar 

  84. Prakash P, Russell RM, Krinsky NI: In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J Nutr 131: 1574–1580, 2001

    Google Scholar 

  85. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y: Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36: 101–111, 2000

    Google Scholar 

  86. Sumantran VN, Zhang R, Lee DS, Wicha MS: Differential regulation of apoptosis in normal versus transformed mammary epithelium by lutein and retinoic acid. Cancer Epidemiol Biomarkers Prev 9: 257–263, 2000

    Google Scholar 

  87. Inoue M, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Hirose K, Hamajima N, Tominaga S: Regular consumption of green tea and the risk of breast cancer recurrence: Follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett 167: 175–182, 2001

    Google Scholar 

  88. Kavanagh KT, Hafer LJ, Kim DW, Mann KK, Sherr DH, Rogers AE, Sonenshein GE: Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 82: 387–398, 2001

    Google Scholar 

  89. Liang Y-C, Lin-Shiau S-Y, Chen C-F, Lin J-K: Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (—)-epigallocatechin-3-gallate. J Cell Biochem 75: 1–12, 1999

    Google Scholar 

  90. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456–7463, 2001

    Google Scholar 

  91. Kampman E, Slattery ML, Caan B, Potter JD: Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control 11: 459–466, 2000

    Google Scholar 

  92. Marcus PM, Newcomb PA: The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 27: 788–793, 1998

    Google Scholar 

  93. Levine AJ, Harper JM, Ervin CM, Chen YH, Harmon E, Xue S, Lee ER, Frankel HD, Haile RW: Serum 25-hydroxyvitamin D, dietary calcium intake, and distal colorectal adenoma risk. Nutr Cancer 39: 35–41, 2001

    Google Scholar 

  94. Platz EA, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannucci E: Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 9: 1059–1065, 2000

    Google Scholar 

  95. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER: Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 340: 101–107, 1999

    Google Scholar 

  96. Slattery ML, Yakumo K, Hoffman M, Neuhausen S: Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 12: 359–364, 2001

    Google Scholar 

  97. Ingles SA, Wang J, Coetzee GA, Lee ER, Frankl HD, Haile RW: Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 12: 607–614, 2001

    Google Scholar 

  98. Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, Bostick RM, Potter JD: Vitamin D receptor polymorphism and the risk of colorectal adenomas: Evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 10: 869–874, 2001

    Google Scholar 

  99. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, Ishiguro S: Inhibition of angiogenesis as a mechanism for inhibition by 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81: 730–733, 1999

    Google Scholar 

  100. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 60: 2304–2312, 2000

    Google Scholar 

  101. Sesink ALA, Termont DSML, Kleibeuker JH, van der Meer R: Red meat and colon cancer: Dietary haem-induced colonic cytotoxicity and epithelial hyperproliferation are inhibited by calcium. Carcinogenesis 22: 1653–1659, 2001

    Google Scholar 

  102. Su LJ, Arab L: Nutritional status of folate and colon cancer risk: Evidence from NHANES I epidemiologic follow-up study. Ann Epidemiol 11: 65–72, 2001

    Google Scholar 

  103. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC: Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 87: 265–273, 1995

    Google Scholar 

  104. Glynn SA, Albanes D, Pietinen P, Brown CC, Rautalahti M, Tangrea JA, Gunter EW, Barrett MJ, Virtamo J, Taylor PR: Colorectal cancer and folate status: A nested case-control study among male smokers. Cancer Epidemiol Biomark Prev 5: 487–494, 1996

    Google Scholar 

  105. Bailey LB, Gregory JF, III: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr 129: 919–922, 1999

    Google Scholar 

  106. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M: Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomark Prev 8: 513–518, 1999

    Google Scholar 

  107. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, Willett WC, Selhub J, Hennekens CH, Gravel R, Rozen R: A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomark Prev 8: 825–829, 1999

    Google Scholar 

  108. Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM: Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer 37: 245–251, 2000

    Google Scholar 

  109. Song J, Medline A, Mason JB, Gallinger S, Kim Y-I: Effects of dietary folate on intestinal tumorigenesis in the Apc Min mouse. Cancer Res 60: 5434–5440, 2000

    Google Scholar 

  110. Song J, Sohn K-J, Medline A, Ash C, Gallinger S, Kim Y-I: Chemopreventive effects of dietary folate on intestinal polyps in Apc+/—Msh2—/— mice. Cancer Res 60: 3191–3199, 2000

    Google Scholar 

  111. Bushman JL: Green tea and cancer in humans: A review of the literature. Nutr Cancer 31: 151–159, 1998

    Google Scholar 

  112. Yang CS, Chung JY, Yang G, Chhabra SK, Lee M-J: Tea and tea polyphenols in cancer prevention. J Nutr 130: 472S–478S, 2000

    Google Scholar 

  113. Metz N, Lobstein A, Schneider Y, Gossé F, Schleiffer R, Anton R, Raul F: Suppression of azoxymethane-induced preneoplastic lesions and inhibition of cyclooxygenase-2 activity in the colonic mucosa of rats drinking a crude green tea extract. Nutr Cancer 38: 60–64, 2000

    Google Scholar 

  114. Uesato S, Kitagawa Y, Kamishimoto M, Kumagai A, Hori H, Nagasawa H: Inhibition of green tea catechins against the growth of cancerous human colon and hepatic epithelial cells. Cancer Lett 170: 41–44, 2001

    Google Scholar 

  115. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39: 102–107, 2001

    Google Scholar 

  116. Tessitore L, Davit A, Sarotto I, Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression. Carcinogenesis 21: 1619–1622, 2000

    Google Scholar 

  117. Wolter F, Akoglu B, Clausnitzer A, Stein J: Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr. 131: 2197–2203, 2001

    Google Scholar 

  118. Chung F-L, Conaway CC, Rao CV, Reddy BS: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287–2291, 2000

    Google Scholar 

  119. Bonnesen C, Eggleston IM, Hayes JD: Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61: 6120–6130, 2001

    Google Scholar 

  120. Goel A, Boland CR, Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin inHT-29 human colon cancer cells. Cancer Lett 172: 111–118, 2001

    Google Scholar 

  121. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP, Jr.: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10: 861–868, 2001

    Google Scholar 

  122. Urban D, Myers R, Manne U, Weiss H., Mohler J, Perkins D, Markiewicz M, Lieberman R, Kelloff G, Marshall M, Grizzle W: Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 35: 429–438, 1999

    Google Scholar 

  123. Singletary E, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM: Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomarkers Prev 9: 1087–1090, 2000

    Google Scholar 

  124. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Jr., Valanis B, Williams JH, Jr., Barnhart S, Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150–1155, 1996

    Google Scholar 

  125. Neuhouser ML, Kristal AR, Patterson RE, Goodman PJ, Thompson IM: Dietary supplement use in the Prostate Cancer Prevention Trial: Implications for prevention trials. Nutr Cancer 39: 12–18, 2001

    Google Scholar 

  126. Waghray A, Schober M, Feroze F, Yao F, Virgin J, Chen YQ: Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res 61: 4283–4286, 2001

    Google Scholar 

  127. Sorlie T, Perou, CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borreson-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874, 2001

    Google Scholar 

  128. Shintani D, DellaPenna D: Elevating the vitamin E content of plants through metabolic engineering. Science 282: 2098–2100, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, USA

    Peter Greenwald & John A. Milner

  2. The Scientific Consulting Group, Inc, USA

    Darrell E. Anderson & Sharon S. McDonald

Authors
  1. Peter Greenwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Milner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darrell E. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sharon S. McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greenwald, P., Milner, J.A., Anderson, D.E. et al. Micronutrients in Cancer Chemoprevention. Cancer Metastasis Rev 21, 217–230 (2002). https://doi.org/10.1023/A:1021202709003

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021202709003

Search

Navigation